

27 November 2024

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

AGREEMENT WITH C14 CONSULTING GROUP

The Directors of Biotron Limited (**Biotron or the Company**) (ASX: BIT) have appointed the USA based C14 Consulting Group LLC (**C14**) to assist and guide the Company in fulfillment of strategic partnerships for its portfolio of antiviral programs including its lead clinical asset BIT225.

C14 is a highly regarded consultancy with a global capability. Led by Martina Molsbergen (Chief Executive Officer), C14 has an enviable track record of securing licence agreements, joint ventures and commercialisation of pharmaceutical patented assets with all levels of pharma from large scale to biotech companies that specialise in orphan and targeted applications.


C14 has demonstrated that it has long standing relationships with a broad cross-section of pharmaceutical companies and a detailed knowledge of the indications and market segments on which each of these companies are currently focusing.

C14 will work with Biotron to refine its commercialisation strategy and provide business development support over coming months. The project and retainer fees together with an outcome-based success component aligns the interests of the parties in achieving one or more commercial outcomes.

Michelle Miller, Biotron's Managing Director, said: *"We are delighted to be partnering with C14. Martina and her team have a long track record in assisting companies such as Biotron to achieve commercialisation of clinical and preclinical assets as well as platform technologies. Their involvement allows us to leverage internal expertise in a cost-effective, efficient manner. With data from the recent clinical trials in hand, together with supporting preclinical and scientific data that demonstrate the potential utility of Biotron's unique approach to treating serious viral infections, the Company is now focused on achieving licencing or partnerships with its antiviral portfolio."*

This announcement has been approved by the Company's Managing Director.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn12419

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional promising preclinical programs including HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329
mmiller@biotron.com.au

Rudi Michelson
Monsoon Communications
+61-3 9620 3333